QALYs in cost-effectiveness analysis: an overview for cardiologists
Related Experiment Video
Updated: Apr 3, 2026

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Olivier J Wouters1, Huseyin Naci1, Nilesh J Samani2
1LSE Health, London School of Economics and Political Science, London, UK.
Abstract:
In recent years, cost-effectiveness data have strongly influenced clinical practice guidelines for several cardiovascular treatments. Economic considerations are increasingly common as health systems are under mounting pressure to maximise value for money. The quality-adjusted life year (QALY)-an outcome measure that expresses the duration and quality of life-is the main pillar of cost-effectiveness analyses. It is widely used in assessments of the clinical and economic value of new cardiovascular treatments, but how the QALY is derived is often unclear to clinicians. In this article, we first explain how QALYs are defined and calculated. We then review a selected set of cost-effectiveness analyses of recently introduced cardiovascular treatments and outline how these studies derived their QALYs. Finally, we discuss the limitations of the QALY and how the presentation of the measure could be improved in cost-effectiveness studies.
More Related Videos
Related Concept Videos
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Cardiomyopathy V: Interprofessional Care
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Coronary Artery Disease V: Interprofessional Care
Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiomyopathy II: Dilated Cardiomyopathy

